Overview of Pancreatic Cancer

Pancreatic cancer (PC) is a recalcitrant and serious disease due to its complex and latent pathogenesis and the lack of early diagnostic methods. The mortality rate of PC is rapidly increasing and PC is expected to be the second most common of all malignant tumors by 2030.

Pancreatic Cancer Detection and Diagnosis

Diagnosis, biomarkers

We briefly describe the diagnostic strategies and the potential biomarkers for the early diagnosis of PC.

Pancreatic Cancer Treatment Strategies

PC treatment strategies

Drugs targeting the DNA damage-repair (DDR) pathway; targeting cancer metabolism; targeting tumor microenvironment; immunotherapy.

Molecular Advances in Pancreatic Cancer

Molecular understanding of PC, new biomarkers

Global analysis of biological systems at the molecular level using high-throughput technologies has led to new advances in improving the diagnosis and treatment of PC.

Pancreatic Cancer Clinical Trial and Targets

Goals of PC clinical trials and research

PC clinical trials are research studies that offer promising new cancer treatments for patients that are not yet readily available.

Overview of Pancreatic Cancer

Pancreatic Cancer Drug Development Services

Small Molecule Drug Development for Pancreatic Cancer

Ease of structural modification, better suitability for clinical needs, and lower cost.

Peptide Drug Development for Pancreatic Cancer

Less immunogenic, more stable ex vivo, higher activity, greater specificity and affinity, easier to synthesize and modify.

Antibody Drug Development for Pancreatic Cancer

More effective and less toxic.

Nucleic Acid Drug Development for Pancreatic Cancer

Safer properties and effective pharmacodynamics.

Oncolytic Viral Therapy Development for Pancreatic Cancer

Showing potential as a new targeted therapeutic approach in PC treatment.

Other Services offered by Alfa Cytology

About Alfa Cytology

Alfa Cytology is a CRO company comprised of scientists, bioinformaticians, oncologists, and so on. Our team works closely and communicates actively to achieve our common goals of helping researchers and professionals understand PC biology, explore new PC therapeutics and protocols, and develop new PC biomarkers.